Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2011Thrombosis and HaemostasisOpen Access

The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention

View Full Paper
Ask AI
Bookmark
Share

Key result

In vitro administration of ALX-0081 completely inhibited platelet adhesion and aggregation in blood samples from CAD patients undergoing PCI, requiring higher concentrations than in healthy controls.

Why the study?

Does in vitro administration of ALX-0081 inhibit platelet adhesion and aggregation in blood samples from CAD patients undergoing PCI?

Population

9 coronary artery disease patients scheduled for elective percutaneous coronary intervention receiving…

Comparison

In vitro spiking of blood samples with ALX-0081… vs In vitro spiking of blood samples with buffer.

Design

Preclinical

Authors

JLJanine E. van LoonPJPeter P.T. de JaegereHVHuub H.D.M. van Vliet

Discussion

Loading...

Member takes

Overview

ALX-0081 may warrant dose titration in CAD-PCI; hypothesis-generating and should not yet change practice.

Structured PICO

Does in vitro administration of ALX-0081 inhibit platelet adhesion and aggregation in blood samples from CAD patients undergoing PCI?

P
Population
20 participants, comprising 9 CAD patients scheduled for elective PCI and 11 healthy volunteers, whose blood samples were evaluated in vitro.
I
Intervention
In vitro spiking of blood samples with ALX-0081 (a bivalent humanised Nanobody binding the A1-domain of von Willebrand factor) at different concentrations.
C
Comparator
In vitro spiking of blood samples with buffer.
O
Outcome
Platelet adhesion and aggregation assessed by flow chamber experiments, ristocetin-induced platelet aggregation (RIPA), and the platelet function analyser (PFA-100™).surrogate

The novel antithrombotic candidate ALX-0081 effectively inhibits platelet adhesion and aggregation in vitro in CAD patients undergoing PCI, with efficacy unaffected by standard co-medications, though higher VWF levels in these patients necessitate higher drug concentrations.

Cite This Study

Loon et al. (2011) studied Coronary artery disease (n=20). ALX-0081 vs. buffer was evaluated on In vitro platelet adhesion and aggregation. In vitro administration of ALX-0081 completely inhibited platelet adhesion and aggregation in blood samples from CAD patients undergoing PCI, requiring higher concentrations than in healthy controls.

synapsesocial.com/papers/6a8b1860c12eaf65c8b1f940https://doi.org/10.1160/th10-12-0804
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Anti-von Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis2010 · 24 citations
  2. 2Reperfusion of cerebral artery thrombosis by the GPIb–VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs2013 · 71 citations
  3. 3The In Vitro Effects of a Novel Vascular Protectant, AGI-1067, on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease2006 · 10 citations
  4. 4Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients2007 · 20 citations
  5. 5Factor XI inhibition in patients with acute coronary syndrome2024 · 10 citations